Sun Pharmaceutical Industries Limited (SUNPHARMA) — Financial Results | 6 August 2025

```json { "summary": "Sun Pharmaceutical reported Q1 FY26 consolidated sales of ₹1,37,861 million, growing 10.1% YoY, with EBITDA of ₹43,017 million up 19.2% and EBITDA margin at 31.1%. Adjusted net profit reached ₹29,961 million, growing 5.7% YoY. India formulations grew 13.9% to ₹47,211 million with #1 market position maintained. Global innovative medicines surged 16.9% to $311 million. Key product launches include Leqselvi for alopecia areata and Checkpoint Therapeutics acquisition adding UNLOXCYT. The company holds a net cash position of $3.1 billion.", "extractedFields": { "keyEvent": "Q1 FY26 earnings: consolidated sales ₹1,37,861 million (+10.1% YoY), EBITDA ₹43,017 million (+19.2%), adjusted net profit ₹29,961 million (+5.7%).", "whatChanged": { "consolidatedSalesGrowthPercent": 10.1, "ebitdaGrowthPercent": 19.2, "ebitdaMarginPercent": 31.1, "adjustedNetProfitGrowthPercent": 5.7, "indiaFormulationGrowthPercent": 13.9, "usBusinessGrowthPercent": 1.4, "emergingMarketsGrowthPercent": 5.1, "globalInnovativeMedicinesGrowthPercent": 16.9, "netCashPositionUsdMillion": 3100, "regulatoryWarningLetterFacilities": ["Mohali", "Dadra", "Halol"], "usGenericBusinessTrend": "down YoY and QoQ" }, "forwardGuidance": { "leqselviRevenueContribution": "Expected in FY26", "unloxcytLaunchTiming": "H2 FY26", "ilumyaPsoriticArthritisFilingTimeline": "End of calendar year 2025", "ilumyaPsoriticArthritisApprovalMonths": 10-12, "glp1ProductLaunchPlanned": "India first wave", "effectiveTaxRate": "~25% for full year FY26", "halolFacilityClearance": "Not expected in current fiscal year" }, "investorTakeaway": "Strong EBITDA growth and margin expansion driven by specialty medicines and India business offset by modest net profit growth, while regulatory headwinds at three US facilities and declining generics require monitoring despite robust pipeline expansion.", "sentiment": "positive" } } ```